reiter outperform rais pt
updat expect phase adjuv melanoma
quick read result softish expect
analyst certif import disclosur see
coupa report strong result stop reiter outperform rais pt
coupa report solid result assess rais growth outlook posit includ better
revenu complet exari acquisit good contribut partner strong pipelin commentari
balanc guidanc impli back-end-load profit cash flow gener ramp may take time investor
gain comfort bottom line believ strong busi momentum coupa display continu futur
quarterli result support valuat moreov anticip new product platform enhanc
announc later month could provid upsid estim reiter outperform rais pt
updat expect phase adjuv melanoma trial bonu
present phase studi abstract alon combin pembrolizumab
keytruda provid investor updat anoth abstract present
nation cancer institut nci util singl concatem mrna technolog believ phase data
present abstract poster give compani partner merck enough visibl convict undertak
robust phase mrna combin pembrolizumab versu pembrolizumab alon adjuv resect
melanoma sinc pembrolizumab current approv treatment adjuv melanoma strong clinic efficaci
eggermont et al nejm find mrk/mrna assert move phase data reassur
despit holiday busi last week ndr hq visit analyst day transact
earn wsj report fix healthcar voter top prioriti elect drug cost rural
hospit closur cite though stanc vari state red vs blue updat event calendar page
quick read result softish expect
spent consider time review close apr result updat jan guidanc
report earlier today past month maintain rather cautiou nearer-term stanc toward
within context continu posit long-term call share own potenti extern challeng
difficult comparison mask underli progress brand today result larg consist think
remain optimist trend compani improv steadili second half
dynam take shape share gradual command higher market valuat
report ep vs our/consensu miss driven lower anticip revenu
margin segment partli off-set below-the-lin impact exhibit
remain pace gener record sale profit result came forecast due notabl
declin custom backlog order toward end quarter continu volatility/uneven demand
given current environ manag lower sale guidanc vs midpoint revis
driven chang off-road if outlook busi unit line prior guid
oper margin expect vs previou rang ep guidanc lower
convers anticip rang vs prior
